| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/23/2005 | WO2005056769A2 Orally-administered live bacterial vaccines for plague |
| 06/23/2005 | WO2005056602A1 Method of screening modified antibody having agonistic activity |
| 06/23/2005 | WO2005056598A2 Laminin-5 modulators and uses thereof |
| 06/23/2005 | WO2005056586A1 Lawsonia intracellularis 26 kd subunit vaccine |
| 06/23/2005 | WO2005056585A2 Sars coronavirus s proteins and uses thereof |
| 06/23/2005 | WO2005056574A2 Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders |
| 06/23/2005 | WO2005056572A2 Clustered multi-antigenic carbohydrate constructs, methods for their preparation and uses thereof |
| 06/23/2005 | WO2005056053A1 Use of goat serum for veterinary treatment |
| 06/23/2005 | WO2005056051A2 Hepatitis b vaccines and compositions |
| 06/23/2005 | WO2005056044A1 Use of c-reactive protein to treat immune complex-mediated renal disease |
| 06/23/2005 | WO2005056024A1 Methods of enhancing stem cell engraftment |
| 06/23/2005 | WO2005055979A2 Ph triggerable polymeric particles or films containing a poly (beta-amino ester) |
| 06/23/2005 | WO2005055957A2 Influenza immunogen and vaccine |
| 06/23/2005 | WO2005055948A2 Epha2, epha4 and lmw-ptp and methods of treatment of hyperproliferative cell disorders |
| 06/23/2005 | WO2005055945A2 Mucoadhesive drug delivery devices and methods of making and using thereof |
| 06/23/2005 | WO2005055936A2 Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
| 06/23/2005 | WO2005055932A2 Therapeutic combinations and methods including irm compounds |
| 06/23/2005 | WO2005042575A3 Method for down-regulation of vegf |
| 06/23/2005 | WO2005040203A3 Msp-3-like family of genes |
| 06/23/2005 | WO2005037999A9 Treatment of cancer using antibodies to lrrc15 |
| 06/23/2005 | WO2005037312A3 Binding molecules for the extra-domain b of fibronectin, used for the detection of atherosclerotic plaques |
| 06/23/2005 | WO2005026200A3 Lawsonia intracellularis subunit vaccine |
| 06/23/2005 | WO2005023849A3 Antigenic peptides of rabies virus and uses thereof |
| 06/23/2005 | WO2005020936A3 Use of lectins to promote oligomerization of glycoproteins and antigenic molecules |
| 06/23/2005 | WO2005019270A3 Endotheliase-2 ligands |
| 06/23/2005 | WO2005017130A3 Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof |
| 06/23/2005 | WO2005007808A3 Hiv polynucleotides and polypeptides derived from botswana mj4 |
| 06/23/2005 | WO2005005630A3 Therapeutic use of lpi, a staphylococcal lectin pathway inhibitor in inflammatory diseases |
| 06/23/2005 | WO2005002505A3 Apolipoprotein c-1 induced apoptosis |
| 06/23/2005 | WO2004078928A3 T cell regulation |
| 06/23/2005 | WO2004071538A3 Topical delivery of cosmetic agents |
| 06/23/2005 | WO2004028564A8 Treatment of pathologies which escape the immune response, using optimised antibodies |
| 06/23/2005 | WO2003102163A8 Methods of diagnosing and treating diabetes and insulin resistance |
| 06/23/2005 | US20050137156 Methods and compositions for generating an immune response |
| 06/23/2005 | US20050137131 UspA1 and UspA2 antigens of Moraxella catarrhalis |
| 06/23/2005 | US20050137130 Medical treatment |
| 06/23/2005 | US20050136502 Treatment of disorders associated with elevated blood glucose or blood pressure |
| 06/23/2005 | US20050136473 Breast specific nucleotide sequences for use as tools in diagnosis, prevention and treatment mammary gland cell proliferative disorders; rational drug design; antitumor agents |
| 06/23/2005 | US20050136467 Neuregulin fusion comprising epidermal growth factor domain for use in treatment and prevention of nervous system and neurodegenerative disorders |
| 06/23/2005 | US20050136435 Amino acid sequences for use in diagnosis, prevention and detection of cancer |
| 06/23/2005 | US20050136422 Neisseria spp. polypeptide, nucleic acid sequence and uses thereof |
| 06/23/2005 | US20050136402 Cancer antigen peptide and/or major histocompatibility complex binding sites for use as tools in detection and tretment of cell proliferative disorders; immunotherapy; genetic vaccine |
| 06/23/2005 | US20050136122 Preparing and using crosslinked, water insoluble, hydrated hyaluronic acid gel particles; in vivo biostability and mechanical properties, usability; ease of injection through fine needles |
| 06/23/2005 | US20050136103 Compositions capable of facilitating penetration across a biological barrier |
| 06/23/2005 | US20050136076 Immunogenic detoxified mutants of cholera toxin |
| 06/23/2005 | US20050136074 Administering antigens capable of causing specific immune reaction(s) directed against an infectious agent and/or cells infected with the infectious agent, and decreasing a different specific immune reaction direct towards the infectious agent, infected cells and/or uninfected cells; immunotherapy |
| 06/23/2005 | US20050136073 Use of microparticles combined with submicron oil-in-water emulsions |
| 06/23/2005 | US20050136072 Excellent therapeutic efficacy on animals having neurological disorders, such as cerebral apoplexy, brain injury, neurological dysfunctions, Alzheimer's disease and myoclonus |
| 06/23/2005 | US20050136071 Hsp70 from arthrobacter |
| 06/23/2005 | US20050136070 Isolation and characterization of the csa operon (ETEC-CS4 Pili) and methods of using same |
| 06/23/2005 | US20050136069 Immunogenic portion of Mycobacterium tuberculosis proteins and monophosphoryl lipid A as adjuvant; vaccines |
| 06/23/2005 | US20050136068 Enzymatically inactive streptococcal C5a peptidase (SCP) conjugated or linked to one or more peptides; effective in immunizing a susceptible mammal against beta-hemolytic Streptococcus |
| 06/23/2005 | US20050136067 Multimeric hybrid gene having a gene sequence coding for an antigenic region of a protein from a first pathogen linked to a gene sequence coding for an antigenic region of a protein from a second pathogen, especially coding for a parainfluenza virus and a respiratory syncytial virus; vaccines |
| 06/23/2005 | US20050136063 Anti-IGFR antibody therapeutic combinations |
| 06/23/2005 | US20050136062 Treatment of IgA1 deposition diseases |
| 06/23/2005 | US20050136060 Antibody fragments are selected from Fab fragments, Fv fragments, single domain antigen binding fragments, scFv and aggregates thereof; for treatment of solid tumor carcinomas |
| 06/23/2005 | US20050136059 Cancer treatment methods using selected antibodies to aminophospholipids |
| 06/23/2005 | US20050136057 Chimeric L chain comprising an L chain C region of a human antibody and an L chain V region of a mouse monoclonal antibody against a human parathyroid hormone related protein; may be used widely in hypercalcemia associated with various cancers |
| 06/23/2005 | US20050136055 CD40 antibody formulation and methods |
| 06/23/2005 | US20050136054 Humanised antibodies |
| 06/23/2005 | US20050136051 Mixing a first molecule comprising IgG4 antibody heavy chain fragments capable of forming hinge region intra-heavy chain disulfide bonds with a second molecule comprising IgG4 antibody heavy chain fragments capable of forming hinge region intra-heavy chain disulfide bonds; incubating |
| 06/23/2005 | US20050136047 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 06/23/2005 | US20050136032 Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| 06/23/2005 | DE10355251A1 Water-based pharmaceutical preparation for treatment of tumors has active ingredient effective against receptor of endothelial growth factor receptor |
| 06/23/2005 | CA2552435A1 Inhibitors of type 2 vascular endothelial growth factor receptors |
| 06/23/2005 | CA2549710A1 Polynucleotides and polypeptides isolated from lactobacillus rhamnosus hn001 materials incorporating them and methods for using them |
| 06/23/2005 | CA2549104A1 Influenza immunogen and vaccine |
| 06/23/2005 | CA2548929A1 Cell death inducing agent |
| 06/23/2005 | CA2548901A1 Use of goat blood serum derived antibodies obtained after challenge with hiv lysate for veterinary treatment |
| 06/23/2005 | CA2548822A1 Mucoadhesive drug delivery devices and methods of making and using thereof |
| 06/23/2005 | CA2548808A1 Monoclonal antibodies that bind or neutralize dengue virus |
| 06/23/2005 | CA2548750A1 Lawsonia intracellularis 26 kd subunit vaccine |
| 06/23/2005 | CA2548567A1 Anti-mpl antibody |
| 06/23/2005 | CA2548310A1 Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders |
| 06/23/2005 | CA2548243A1 Integrin aiib.beta.3 specific antibodies and peptides |
| 06/23/2005 | CA2548180A1 Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
| 06/23/2005 | CA2548149A1 Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption |
| 06/23/2005 | CA2548015A1 Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse |
| 06/23/2005 | CA2547425A1 Orally-administered live bacterial vaccines for plague |
| 06/23/2005 | CA2546769A1 Production of diphtheria toxin |
| 06/23/2005 | CA2544018A1 Compositions and methods to reduce mutagenesis |
| 06/23/2005 | CA2490218A1 Extracorporeal photopheresis in combination with anti-tnf treatment |
| 06/22/2005 | EP1544617A2 Use of a Nifie 14 binding substance for the diagnosis and treatment of cancer |
| 06/22/2005 | EP1544211A1 LSA-5 pre-erythrocytic stage antigen of plasmodium falciparum, immunogenic composition comprising said antigen, and vaccines against malaria |
| 06/22/2005 | EP1543838A1 Feline infectious peritonitis vaccine |
| 06/22/2005 | EP1543837A1 Virus-like particle (VLP) as vaccine |
| 06/22/2005 | EP1543836A1 Recombinant Vibrio cholerae strain and vaccine comprising said strain |
| 06/22/2005 | EP1543835A1 Method of transforming autoimmune-disease-causing hapten-antigens (hapigens) of an organism into complete antigens |
| 06/22/2005 | EP1543166A2 Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome |
| 06/22/2005 | EP1543165A2 Assays for assembly of ebola virus nucleocapsids |
| 06/22/2005 | EP1543145A2 Antifungal therapeutic targets |
| 06/22/2005 | EP1543113A1 Chicken astrovirus type 2 |
| 06/22/2005 | EP1543109A2 Substances for preventing and treating autoimmune diseases |
| 06/22/2005 | EP1543039A1 Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes |
| 06/22/2005 | EP1543037A2 Dendritic cell pontentiation |
| 06/22/2005 | EP1543034A2 Treatment and prophylaxis with 4-1bb-binding agents |
| 06/22/2005 | EP1543024A2 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use |
| 06/22/2005 | EP1542729A1 Stable immunogenic product comprising antigenic heterocomplexes |
| 06/22/2005 | EP1542725A2 Method of humanizing immune system molecules |
| 06/22/2005 | EP1542724A2 Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof |